Member Info for Diversified

Your right sax. God knows what I was looking at lol

415k shares traded on Helsinki market, massive volume for that market.

WHO briefing for today considerably later than usual for a Monday. You never know! Seems to be more to this than meets the eye though

In Finland right now, just jumped 15 minute delayed

It’s definitely getting stronger over in Finland. This guy on twitter seems to confirm an update is imminent which happens to coincide with a positive share price reaction and Friday’s publicity.

The sun is shinning, positive outcome seems to be likely Imo.

*feel of

£4.58 so this should tick up nicely here. It definitely has the few of big news imminent.

New treatment.

Anyone think this might be a new treatment in relation to COVID19?

With the trial to begin this month and top U.S. universities such as Harvard amongst others taking part. I can only hope and think of the traction that this company deserves from both the US and global investors for the transformational treatment that is traumakine. Not many companies would reattempt or have such traction with key global opinion leaders for a phase 2/3 trial that traumakine has without absolute confidence that it was a winner second time round.

Traumakine is now being made in batches with a new state of the art manufacturing facility for future commercial production, with a new partner yet to be announced. Further endorsement and a box ticked for what is to come imo.

We then have key opinion leaders discussing the future of cancer treatments with what sounds to be Clevergen at the heart of discussions (as per twitter), something that wouldn’t happen without further updates imminent imo. This could well be a blockbuster in its own right.

Updates are imminent, and with or without an effective Covid/traumakine treatment, I am certain that the future of this company is as exciting as most have to offer.

Massive ramp or not, I’d rather be in an under the radar stock like Farn than a pumped up fairy tail that promises the world but has very little in its armory to back it up. An exciting 6/12 months ahead, I think most will agree.

https://twitter.com/karitikkinen/status/1294646959727411202?s=21

Both are still being trialed individually

I get the impression that we are going to get an update imminently, so much news due by the end of this quarter, all of which could be transformational.

What was the reason for the article unless buoyed by a positive outcome. Sounds like the sun is shining and the company is about to embark in a transformational period through positive trials. You wouldn’t spend most of your time on a plane unless your treatment was gaining commercial traction.

This is very positive imo.

S*it some of that made no sense, back to sleep!

Reporting from the trials is outside of Farons control, eg. Remap and Solidarity.

What I find strange is that we were promised an update on the new state of the art expansion of interferon for future dispatch to a manufacturer. I would of thought that manufacturing discussions are taking place.

We then have the update or initiation of the Hibiscus trial funded by a third party starting by the end of September.

We can also expect an update on Clevergen which is the real game changer.

With the share price fluctuating until then, in very much the same way that SNG did but it’s transformational news, all we can do is sit and wait. I would of thought that most have now be positioned according to their desired level of risk.

It hasn’t taken much volume to send the share price in either direction, but I think it’s fair to say that interferon has a role to play in the fight against covid. Much depends on the point of treatment during the cycle and hopefully the way in which it is administered.

Yesterday’s WHO update was more about donation/funding than providing physical updates on progress. That was extremely frustrating, however to update on progress before the event runs the risk of further miss reporting on social media and other news streams.

Venrock Healthcare Capital Partners III, L.P. who have been building a position have a direct relationship with Giliad.

https://www.venrock.com/

Coincidence, maybe, maybe not

https://news.sky.com/story/coronavirus-more-than-three-million-people-in-england-have-had-covid-19-antibody-study-suggests-12048413

Another 200k tests planned for the autumn. Global distribution of the Ukrtc test needed!

Significant accumulation from many institutions globally, very exciting.

The longer the solidarity trial goes on for, the higher the probability of success will be imo. The solidarity trial has dropped treatments that were ineffective, so for IFN-B and Remdisiver to still be under review, they must be seeing some positive results.

We then have the recently initiated NIH clinical trial for Remdisiver plus IFN-B-1a. Key opinion leaders would have identified this as a potential candidate by considering the evidence to date.

We have the HIBISCUS study in the US that will also gain us significant attention from US investors. This was to be in place by end of Q3 with 3rd party financing.

We then have SNG001 and all the hype around that treatment and it’s positive results to date.

I take comfort in the fact that for every country that are part of the Solidarity trial, any positive treatment that were to come from this trial would have full access to those countries that had taken part.

Based on reports from Columbia, South Africa and Nigeria that they are initiating trials for Interferon beta. Then taking into consideration the time that has elapsed since other treatments have been dropped and over what period. I am personality expecting an update from the solidarity trial in October. With additional updates on Clevergen in September.

More imminently we should hear about the new American trials and the ramp up in state of the art production. Even potential forward orders for the treatment/traumakine.

Of course news could drop imminently, but it won’t hurt to manage expectations.

Given the size of the potential market for IFN-B1a they need to find multiple lines of product to meet demand. Cost also has to be considered and at which point the treatment is delivered. For any successful treatment their will be a market for all.